Best Neurology Companies in Israel
The 124 best Neurology companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Insightec.
Israel's neurology sector has quietly built one of the most fundable pipelines outside the U.S. — 124 companies tracked here, ranked by disclosed equity funding and recent momentum, with $1.5B in total capital raised across the cohort. Insightec alone accounts for $574M of that, a figure that skews the average hard, but BlueWind Medical ($64M) and BrainStorm Cell ($35M) show there's real depth below the headline. One unicorn. Active backers including Peregrine Ventures and Israel Brain Technologies keep deal flow moving. The [global neurology market sits at roughly $112.5B in 2025, tracking toward $180.2B by 2032 at a 6.9% CAGR](https://www.biospace.com/neurology-market-expected-to-witness-sustained-growth), driven by an aging population and accelerating neuroimaging capabilities. So the macro tailwind is real.
What's interesting right now is where attention is clustering. Coverage is flat on traditional CNS drug development, but cognitive aging, post-concussion syndrome, and chronic traumatic encephalopathy are pulling serious research dollars. Stress-induced neuroinflammation is emerging as a connective thread across several of these themes, and if you follow the science, epilepsy care infrastructure is getting renewed clinical attention too. I'd watch whether Israeli companies, particularly those in neuromodulation and cell therapy, move to position against those trends before the next funding cycle tightens.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Israel
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Insightec 🦄 Provider of MR-interfaced ultrasound technology-based device for cancer and neurology 89Patents top 17%Moat top 17%Funding top 18%Innovation top 24% All 10 signals ▾Patentstop 17% Moattop 17% Fundingtop 18% Innovationtop 24% Talenttop 28% Markettop 29% Growthtop 32% Techtop 33% Globaltop 33% Newsbottom 21% Patents: 390 patents matched (strict assignee match) · 133 filings since 2022 vs 124 in 2017-21 Moat: Editorial + unicorn rating 9/10 · IP moat: 390 patents rank vs industry peers · Fliar Intelligence Index 89/100 | $574M | 24 mo ago | Series G | Oded Tamir Co-Founder & COO | 144 | WordPressApple iCloud MailMySQL+36 | 390 patents Image-guided focused ultrasound therapy with real-time monitoring and skull aberration correction | 1 award |
| 2 | Prilenia Developer of therapeutics for the treatment of neurogenerative diseases | $134M | 55 mo ago | Series B | Michael R Hayden Founder & CEO | 39 | BugHerdApple iCloud MailMicrosoft 365+19 | — | — |
| 3 | BrainsGate Electrical stimulation therapy for CNS diseases | $97M | 66 mo ago | Series F | — | 22 | — | 61 patents Implantable neural stimulation devices and delivery mechanisms for therapeutic neuromodulation | — |
| 4 | Rapid Medical Developer of neurovascular interventional devices such as distal access & microcatheters | $79M | 61 mo ago | Series D | — | 120 | DudaNginxSnowplow Analytics+12 | 219 patents Minimally invasive vascular access devices and guidewire actuation/control technologies. | — |
| 5 | Novaremed Developing tyrosine kinase modulator for the treatment of neuropathic pain | $72M | 64 mo ago | Series B | — | 10 | — | 98 patents Novel small‑molecule anti‑inflammatory and analgesic compounds for pain and autoimmune therapy | — |
| 6 | Ornim Non-invasive measurement for cerebral and tissue blood flow | $70M | 118 mo ago | Deadpooled | — | 43 | — | — | — |
| 7 | BlueWind Medical Developer of neurostimulation device for the treatment of overactive bladder 50Patents top 39%Funding top 40%Innovation top 43%Tech top 46% All 9 signals ▾Patentstop 39% Fundingtop 40% Innovationtop 43% Techtop 46% Moattop 47% Markettop 50% Talentbottom 49% Globalbottom 40% Newsbottom 22% Patents: 73 patents matched (strict assignee match) · 23 filings since 2022 vs 38 in 2017-21 Funding: Raised $64.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $64M | 1 mo ago | Series B | Dan Lemaitre Chairman & CEO | 95 | WordPress Block EditorWordPressMySQL+22 | 73 patents Wireless implantable neurostimulation devices and antenna designs for neuromodulation therapy. | 1 launch |
| 8 | BrainQ Developer of AI-powered electromagnetic stimulation technology for stroke disability recovery | $49M | 53 mo ago | Series B | Yaron Segal Founder & CTO | 44 | WebflowYouTubeGSAP+16 | 3 patents Non‑invasive electromagnetic neurostimulation for nerve regeneration and repair | — |
| 9 | D-Pharm Drug re-engineering technology to develop new drugs for CNS indications | $48M | 241 mo ago | Series D | Ofra Yamin CEO | 76 | — | — | — |
| 10 | Brainsway Develoepr of noninvasive neurostimulation treatments for mental health disorders 48Funding top 29%Tech top 35%Patents top 37%Moat top 41% All 11 signals ▾Fundingtop 29% Techtop 35% Patentstop 37% Moattop 41% Innovationtop 43% AItop 45% Globalbottom 49% Talentbottom 49% Growthbottom 47% Newsbottom 24% Marketbottom 23% Funding: Raised $40.5M across 4 rounds · 4 rounds over 12 yrs (0.3/yr) Tech: 59 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 48/100 | $40M | 20 mo ago | Public | Hadar Levy Chief Executive Officer | 1 | WordPressMySQLPHP+34 | 112 patents Non‑invasive transcranial magnetic stimulation hardware and closed‑loop brain‑stimulation systems | — |
| 11 | Mapi Pharma Clinical stage pharmaceutical company developing extended release versions of generic drugs. | $40M | 72 mo ago | Series B | Ehud Marom Chairman & Ceo | 38 | WordPressMySQLPHP+15 | 325 patents Patents concentrated in health & consumer products | — |
| 12 | BrainStorm Cell Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD 48Funding top 23%Patents top 31%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 23% Patentstop 31% Moattop 38% Innovationtop 39% Techtop 39% Talentbottom 49% Marketbottom 41% Growthbottom 40% Globalbottom 39% Newsbottom 23% Funding: Raised $34.9M across 10 rounds · 10 rounds over 14 yrs (0.7/yr) Patents: 75 patents matched (strict assignee match) · Lead CPC: A61K35/28 (+2 more areas) rank vs industry peers · Fliar Intelligence Index 48/100 | $35M | 4 mo ago | Public | Chaim Lebovits Chief Executive Officer | 37 | WordPressMySQLPHP+27 | 75 patents Exosome-based biologics delivering neurotrophic factors for regenerative and pulmonary therapies | — |
| 13 | NovaSight Provider of eye-tracking-based solutions for vision assessment and treatment | $20M | 51 mo ago | Series B | Michael Belkin Co-Founder | 22 | WordPressMySQLPHP+31 | 53 patents Vision therapy and diagnostic devices for refractive errors, amblyopia, and ocular motility | — |
| 14 | Kadimastem Stem Cell for the treatment of diabetes mellitus and amyotrophic lateral sclerosis (ALS) | $18M | 55 mo ago | Public | — | 31 | WixSentryBootstrap+12 | 54 patents Generation and purification of pancreatic endocrine cells for therapeutic applications | 1 partnership |
| 15 | RetiSpec Non-invasive eye scanner for early detection of Alzheimer’s Disease. 37Innovation top 38%Funding top 38%Product top 46%Tech bottom 43% All 6 signals ▾Innovationtop 38% Fundingtop 38% Producttop 46% Techbottom 43% Globalbottom 38% Marketbottom 34% Innovation: 2 product lines · Deep-tech classification: Tech Hardware Funding: Raised $17.0M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $17M | 22 mo ago | Series A | — | 23 | — | — | 1 partnership |
| 16 | Filterlex Medical Developer of an embolic protection device | $17M | 53 mo ago | Series B | Eyal Teichman Co-Founder | 11 | — | — | — |
| 17 | Therapix Biosciences Developing cannabinoid-based therapies for CNS disorders | $13M | 63 mo ago | Acquired | Amitay Weiss CEO | — | — | 36 patents Novel combination therapeutics using cannabinoids/opioids with N‑acylethanolamines and CD3 antibodies | — |
| 18 | PainReform Specialty pharmaceutical company that develops products for the treatment of pain 32Product top 24%Funding top 34%Growth top 35%Moat top 38% All 11 signals ▾Producttop 24% Fundingtop 34% Growthtop 35% Moattop 38% Newstop 43% Talentbottom 49% Innovationbottom 44% Techbottom 42% Patentsbottom 39% Globalbottom 35% Marketbottom 21% Product: 2 product launch events in 12 mo · 6 distinct product lines Funding: Raised $12.0M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $12M | 11 mo ago | Public | Michael Mulholland Chief Executive Officer | 6 | WordPressMySQLPHP+16 | 22 patents Sustained-release depot formulations for local anesthetics and hydrophobic drugs | — |
| 19 | Perflow Medical Medical devices for neurovascular treatments | $12M | 100 mo ago | Series A | — | 33 | — | 47 patents Endovascular devices for aneurysm occlusion and removal of vascular blockages. | — |
| 20 | Neurolief Wearable device for neurological and neuropsychiatric disorders 27Patents top 36%Talent top 38%Innovation top 39%Funding top 46% All 10 signals ▾Patentstop 36% Talenttop 38% Innovationtop 39% Fundingtop 46% Producttop 47% Moattop 47% Globalbottom 35% Marketbottom 28% Techbottom 26% Newsbottom 22% Patents: 55 patents matched (strict assignee match) · 18 filings since 2022 vs 29 in 2017-21 Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $11M | 2 mo ago | Series A | Shmuel Shany Co-Founder | — | WordPressApple iCloud MailMicrosoft 365+14 | 55 patents Wearable transdermal neurostimulation headsets integrating biosensing for therapeutic monitoring | 1 job opening |
| 21 | SMT Research and Development Embolic protection device | $10M | 182 mo ago | Deadpooled | Nikolaus Schweinert CTO & Founder | — | — | — | — |
| 22 | Neuronix Develops new methods for treatment of alzheimer's disease for long term improvement of quality of life | $8M | 124 mo ago | Deadpooled | — | 16 | — | 21 patents Non‑invasive brain stimulation systems for CNS disorder treatment and cognitive enhancement | — |
| 23 | Todos Medical Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders | $7M | 56 mo ago | Public | — | 7 | — | 42 patents Blood-based infrared spectroscopy for Alzheimer’s and cancer biomarker detection | — |
| 24 | NurExone Developer of drugs for neurological disorders 40Funding top 36%Tech top 36%Talent top 38%News top 46% All 7 signals ▾Fundingtop 36% Techtop 36% Talenttop 38% Newstop 46% Growthtop 47% Marketbottom 29% Globalbottom 25% Funding: Raised $7.2M across 9 rounds · 9 rounds over 2 yrs (4.5/yr) Tech: 34 technologies across 5/8 capability areas · Cloud: Akamai rank vs industry peers · Fliar Intelligence Index 40/100 | $7M | 3 mo ago | Public | Lior Shaltiel Chief Executive Officer | — | WordPressMySQLPHP+27 | — | 1 partnership |
| 25 | ImmunoBrain Developer of neuroprotective immune therapies for neurodegenerative diseases | $5M | 57 mo ago | Funding Raised | Michal Schwartz Co-Founder | 14 | WordPressMySQLPHP+18 | — | — |
| 26 | NeuroDerm Therapies for Parkinson’s disease (PD) and other CNS disorders | $2M | 156 mo ago | Acquired | Ayelet Altman CEO | 55 | Apple iCloud MailPlyrUIKit+13 | 450 patents Formulations and delivery methods for Parkinson’s disease therapeutics. | — |
| 27 | miCure Therapeutics Developer of microRNA therapeutics and diagnostics for CNS disorders | $2M | 144 mo ago | Seed | Michel Horovitz CEO | — | — | 8 patents Targeted microRNA therapeutics and neuron-specific oligonucleotide delivery platforms | — |
| 28 | Ceretrieve Developer of medical devices for treating ischemic stroke | $2M | 65 mo ago | Seed | Ronen Jaffe Co-Founder | 7 | — | 16 patents Embolus removal catheters and retrieval devices for vascular interventions | — |
| 29 | BioLert Smartwatch wearable for the detection of epilepsy seizures | $2M | 174 mo ago | Funding Raised | Avi Yaron CEO | — | — | 7 patents Wearable medical devices for real-time epileptic seizure detection and monitoring. | — |
| 30 | Thrombotech Peptide drug for the treatment of ischemic stroke | $1M | 171 mo ago | Acqui-Hired | Ruth Yakar CEO | — | — | 22 patents Therapeutic peptides modulating plasminogen activators for cardiovascular and hypertension treatment | — |
| 31 | NeuroSense Therapeutics Developer of therapeutics for neurodegenerative diseases | $1M | 23 mo ago | Public | — | 14 | WordPressMySQLPHP+23 | 27 patents Combination drug formulations targeting neuroinflammatory and neuronal disorders | — |
| 32 | NexSig Neurological Examination Technologies Neuropsychological assessment software for the diagnosis of cognitive impairments | $926K | 226 mo ago | Deadpooled | Vered Aharonson CEO | — | — | — | — |
| 33 | Neurosteer Developer of a wearable band and a cloud platform for monitoring brain signals | $115K | 89 mo ago | Funding Raised | — | 13 | DudaNginxAmazon Web Services+14 | 24 patents Integrated neurofeedback and hybrid invasive/noninvasive brain stimulation technologies | — |
Top 12 Neurology companies in Israel
#1
Series B · Herzliya, Tel Aviv · founded 2010 · 95 employees$64Mraised▾
Developer of neurostimulation device for the treatment of overactive bladder. The flagship product of the company is "Renova" a wireless device that delivers targeted electric stimulation to the nerve for the treatment of patients with an Overactive Bladder and associated symptoms of urinary urgency and frequency.
- May 2026Series B$47.8M
- May 2026Conventional Debt—
- May 2022Series B$64M
#2
Public · Petah Tikva, Central District · founded 2000 · 37 employees$34.9Mraised▾
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson’s disease (PD). NurOwn is BrainStorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. Its platform technology essentially converts MSCs into living drug delivery systems for NTFS. They use animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury.
- Feb 2026Post IPO$1M
- Jun 2020Grant (prize money)$500K
- Apr 2020Grant (prize money)$1.5M
- Nov 2019Grant (prize money)$495.3K
#3
Series A · Herzliya, Tel Aviv · founded 2012$11Mraised▾
Neurolief is focussed on developing a wearable platform technology for brain neuromodulation. It is developing a wearable device that enables the safe and effective treatment for neuro disorders such as migraine and depression without interfering with the patient's daily activities. As of September 2016, the device is in clinical development.
- Mar 2026Series A$6M
- Aug 2025Series A$5M
- 2015Seed—
#4
Public · Haifa, Haifa District · founded 2020$7.2Mraised▾
Developer of drugs for neurological disorders. It biologically-guided exosome therapy based on ExoTherapy platform technology for the treatment of acute spinal cord injury. It use exosomes as nanocarriers to deliver drug for neuron rewiring and regeneration.
- Mar 2026Post IPO$279.9K
- Aug 2025Post IPO$147.8K
- Apr 2025Post IPO$1.6M
- Jan 2025Post IPO$434.5K
#5
Series G · Tirat Carmel, Haifa District · founded 1999 · 144 employees$574.2Mraised▾
Provider of MR-interfaced ultrasound technology-based device for cancer and neurology. The company's Exablate Neuro platform focuses on sound waves and guided by MRI to patients with medication-refractory essential tremor, Parkinson's Disease, uterine fibroids, and pain palliation of metastatic bone.
- Jun 2024Series G$150M
- Sep 2022Conventional Debt—
- Nov 2020Series F—
- Mar 2020Series F$150M
#6
Public · Herzliya, Tel Aviv · founded 2007 · 6 employees$12Mraised▾
Painreform is a specialty pharmaceutical company that develops products for the treatment of pain. It is focused on reformulations of established pain drugs by applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patients convenience as well as faster return of motor function. Its lead product PRF-110 provides a prolonged action of the local analgesic agent ropivacaine, a generic local analgesic drug. The company has applied for 2 PCT applications on its platform technology and on its lead product
- Jul 2025Post IPO$600K
- Mar 2021Post IPO$6M
- Jul 2018Series A$12M
#7
Public · Jerusalem, Jerusalem District · founded 2003 · 1 employees$40.5Mraised▾
Develoepr of noninvasive neurostimulation treatments for mental health disorders. The company uses proprietary technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment. It is used to treat depressive episodes in patients suffering from Major Depressive Disorder.
- Sep 2024Post IPO$20M
- Dec 2017Post IPO$8.5M
- Jan 2016Grant (prize money)$163.7K
- Mar 2014Post IPO$11.8M
#8
Series A · Tel Aviv, Tel Aviv · founded 2015 · 23 employees$17Mraised▾
RetiSpec was an early stage medical device startup developing a non-invasive eye scanner for early detection of Alzheimer’s Disease. The company was selected as the finalists at the MassChallenge Boston accelerator & had won 1st place at the JNF Lions-Den competition in Toronto & at the 2016 Partners Connected Health and AARP startup competition in Boston. As of Jan 2017, the company hasn't disclosed its product development details.
- Jul 2024Series A$10M
- Oct 2019Grant (prize money)$500K
- Jun 2017Grant (prize money)$50K
#9
Series B · Herzliya, Tel Aviv · founded 2018 · 39 employees$133.5Mraised▾
Developer of therapeutics for the treatment of neurogenerative diseases. It has developed its lead product Pridopidine, a sigma-1 receptor (S1R) agonist, for the treatment of multiple movement disorders and neurodegenerative diseases in adults and children. The compound is also shown to treat Huntington's disease (phase III), ALS, Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and other conditions.
- Nov 2021Series B$43M
- Jun 2020Series A$62.5M
#10
Series F · Caesarea, Haifa District · founded 2000 · 22 employees$97Mraised▾
BrainsGate is developing a platform technology for electrical stimulation of the sphenopalatine ganglion (SPG), a nervous center known to increase cerebral blood flow. Focus application is acute ischemic stroke. Has developed an implantable electrode which can be activated through an external system temporarily attached to the patient's cheek.
- Dec 2020Series F$14M
- Jan 2015Series C$11M
- Aug 2011Series C$20M
- Aug 2008Series C$27.5M
#11
Series B · Jerusalem, Jerusalem District · founded 2011 · 44 employees$48.8Mraised▾
Developer of AI-powered electromagnetic stimulation technology for stroke disability recovery. The investigational therapy uses tailored, low-intensity, low-frequency electromagnetic stimulation to enhance the brain’s recovery process. The device is designed for safe use in clinical and home settings. The therapy aims to help patients regain independence and improve neurological conditions.
- Dec 2021Grant (prize money)$56.6K
- Aug 2021Series B$40M
- Jan 2020Grant (prize money)$2.5M
- Nov 2018Grant (prize money)$56.9K
#12
Series B · Petah Tikva, Central District · founded 2008 · 10 employees$72.4Mraised▾
Novaremed is focussed on developing drugs for neuropathic pain. Based on its proprietary library of small molecules identified from a biological substance with anti-inflammatory therapeutic properties, it is developing its pipeline. Its lead candidate NRD135S-E1 is a first-in-class tyrosine kinase modulator currently in phase 2 trials for the treatment of neuropathic pain via a unique and new mechanism of action.
- Jan 2021Series B$50M
- Sep 2020Series A$2.7M
- Sep 2019Series A$2.6M
- Aug 2018Series A$6.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Israel
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 232 Israel-affiliated papers.
- Hebrew University of Jerusalem61
- Hadassah Medical Center55
- Tel Aviv University47
- Ben-Gurion University of the Negev24
- Hadassah Academic College22
- Deep brain stimulation10
- Subthalamic nucleus7
- Stimulation5
- Anesthesia5
- Parkinson's disease4
- Deep brain stimulation21→27
- Neurostimulation2→8
- Electrophysiology1→5
- Transcranial direct-current stimulation1→5
- Subthalamic nucleus12→15
- Neurostimulation1→5
- Essential tremor1→4
- Stimulation3→4
Where neurotech is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.